Russian vaccine trial sees antibodies form

Preliminary results from Russian coronavirus vaccine trials have suggested the candidates saw no serious adverse events and that the jab also elicited an antibody response.

Results from two earlyphase non- randomised vaccine trials in a total of 76 people indicate that two formulations of a two- part vaccine have a good safety profile with no serious adverse events detected over 42 days.

The findings, published in The Lancet, also found the candidates induced an antibody response in all participants within 21 days. Secondary outcomes from the trial suggest the vaccines also produce aT-cell response within 28 days.

The paper reports findings from two small phase 1- 2 trials lasting 42 days.

One looked at a frozen formulation of the vaccine, and another involving al yo phil is ed( freezedried) formulation.

It is envisaged that the frozen formulation will be for large- scale use, using existing global supply chains for vaccines.

The freeze- dried formulation was developed for hard- to- reach regions as it is more stable and can be stored at 2C- 8C.